This receptor is frequently expressed on glioblastoma cells and CAR-engineered, autologous primary CD8+ T lymphocytes targeting IL13Rα2 were evaluated for treatment of recurrent glioblastoma. This evidence concerns the gene IL13RA2 and glioblastoma.